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Abstract
• UCTD is also known as incomplete lupus erythematosus, 
undifferentiated systemic rheumatic disease, latent lupus, and 
potential lupus.  
• Rheumatology shortage of 50% by 2025: UCTD patients will face 
long wait times and declined referrals. (Basen, 2016). 
• DMARDs, such as hydroxychloroquine: proven effective in treating 
patients with UCTD, SLE, and RA.
• Primary care providers (PCP) play a key part in early recognition 
and referral of patients with UCTD symptoms. 
• Scholarly project focus is review of available literature which 
demonstrates the use of csDMARDs by PCPs in treating UCTD 
patients. 
• Projected outcome is that pain and functional impairment can be 
decreased via treatment by PCP’s using hydroxychloroquine in the 
absence of rheumatology intervention.
Literature Review
Applicability to Clinical 
Practice
Acknowledgements
Discussion
• Puchner et al. (2016) and Badley et al. (2015) identified the role of 
primary care providers to be significant in treating early connective 
tissue disease due to the rheumatology shortages.
• Small percentage of the primary care physicians acknowledged 
having initiated DMARD therapy, but the majority of general 
practitioners pointed out that they would prescribe DMARDs. 
(Puchner et al., 2016) 
• Possible delays in referrals to rheumatology resulted in long-term 
harm, including joint inflammation and destruction
• Primary care providers comfort level and knowledge of DMARD 
therapy use can be limiting factors
• Current studies have provided significant data supporting the use of 
DMARDs in treating UCTD, but there is minimal evidence that 
supports the use of DMARDs by primary care providers.
• Undifferentiated connective tissue disease (UCTD) is an 
autoimmune disease that presents similarly to other rheumatic 
conditions but fails to meet laboratory requirements which indicate a 
specific disease such as rheumatoid arthritis, systemic lupus 
erythematous, Sjogren's or scleroderma.  
• UCTD presentation can include arthralgias, myalgias, fatigue, fever, 
Raynaud’s phenomenon and sicca like symptoms with a positive 
antinuclear antibody (ANA) test. 
• Patients with UCTD symptoms are normally referred to rheumatology 
but a shortage exists leaving primary care providers to treat UCTD 
patients. 
• Using disease modifying antirheumatic drugs (DMARDs) such as 
hydroxychloroquine is an option but it is not commonly prescribed by 
PCPs. 
• The study’s purpose is to determine if PCPs can effectively initiate 
and appropriately manage UCTD patients using DMARDs, such as 
hydroxychloroquine, to reduce the patient’s symptoms and functional 
impairment.
• Using DMARDs, NSAIDs and low dose corticosteroids in UCTD 
patients provided by PCPs can improve arthralgias, myalgias, fever, 
and functional limitations. 
• Majority of rheumatologists and PCPs feel UCTD patients should be 
referred to rheumatology for treatment, yet there is some evidence 
that PCPs can also initiate and manage the treatment effectively.  
• In the absence of rheumatology, PCPs using DMARDs such as 
hydroxychloroquine can safely and effectively provide treatment for 
these patients
Berman, J. R. (2017, July). Undifferentiated Connective Tissue Disease: In-Depth Overview. Retrieved from 
https://www.hss.edu/conditions_undifferentiated-connective-tissue-disease-overview.asp.
• Primary care providers have an opportunity to greatly impact the 
progression and detrimental effects of UCTD using early 
csDMARDs therapy.
• Given the gap and lack of accessibility to rheumatologists by 
patients with UCTD, health care sector could collaborate with 
primary care providers to offer formal training. 
• Rheumatology organizations should consider the possibility of 
working with physician assistant programs and schools of nursing to 
integrate rheumatology into the curriculum. (Solomon et al., 2014)  
• Greater comfort in prescribing DMARDs could be achieved by 
altering the design of educational programs for primary care 
providers.  (Gerneau et al., 2012). 
• There continues to be a need for improving awareness and 
education regarding diagnosing and treating UCTD patients in 
primary care where early treatments with DMARDs make a 
significant impact on a patient’s health and quality of life. 
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Statement of the Problem
• Use of csDMARDs by rheumatologists has the potential to control 
rheumatic diseases.
• UCTD patients often lack access to timely treatment by 
rheumatology.
• Delaying treatment may result in ongoing symptoms such as but not 
limited to arthralgias, myalgias, and functional impairment.
• UCTD patients who do not have access to rheumatologists frequently 
look to their primary care providers for treatment
• Question:  Is it possible to effectively decrease the inherent 
symptoms of UCTD by offering early interventions using csDMARDs 
such as hydroxychloroquine through a primary care provider?
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Clinical Features of UCTD % Patients
Fatigue 83
Raynaud’s syndrome 61
Arthralgia 56
Muscle pains 56
Fever 51
Polyarthritis 51
Xerophthalmia 29
Xerostomia 27
Weight loss 24
Thyroiditis 19
Oral aphthosis 17
Lymphadenopathy 17
Urticaria 17
Synovitis 15
Serositis 14
Photosensitivity 12
Erythema nodosum 9
Other 7
In the absence of rheumatology, can primary care providers effectively 
initiate and appropriately manage patients with UCTD using 
conventional synthetic disease modifying antirheumatic drugs, such as 
hydroxychloroquine, to reduce patient’s symptoms and functional 
impairment?
Research Question
Introduction
Clinical and Serological Presentation of UCTD
• UCTD clinical course includes Raynaud’s phenomenon, sicca 
symptoms, arthralgias, arthritis and mucocutaneous manifestations -
photosensitivity, malar rash, and oral aphthous ulcers as well as a 
positive ANA for at least 3 years (Mosca, 2004)
Prevalence of UCTD
• UCTD patients are predominantly middle-aged females with disease 
onset between 32-44 years of age. (Conti et al., 2010)
• 20% of newly referred patients to rheumatology may fall within the 
undifferentiated profile excluding rheumatoid arthritis. (Mosca et al. 
2011)
• Between 50-70% patients remain undifferentiated. (Conti et al., 2010 
& Mosca et al., 2011)
Prescriptive Treatment Methods for UCTD
• Use of hydroxychloroquine, NSAIDs, and low dose corticosteroids 
was sufficient to maintain UCTD in an inactive status including a 
reduction of arthralgias, functional limitations, myalgias and fever. 
(Conti et al., 2010).
• It is recommended that early UCTD patients have strict follow up at 
least every six months. (Conti et al., 2010). 
• One-third of rheumatologists and general practitioners agreed that 
when rheumatology availability is limited, then csDMARDs could also 
be initiated by a general practitioner. (Puchner et al., 2016). 
Role of Primary Care in the Management of UCTD
• On average, 10.3% of the patients made at least one visit to primary 
care for inflammatory arthritis. (Badley et al., 2015)
• Primary care providers were less likely to use csDMARDs to treat 
connective tissue disease symptoms. (Badley et al., 2015)
• DMARD treatment in primary care was imperative because 
unnecessary referrals of patients diagnosed with rheumatic condition 
increased the work overload in rheumatology practices. (Puchner et 
al., 2016).
• Although csDMARD therapy is not commonly initiated by primary 
care physicians, DMARDs are recommended, especially when timely 
access to rheumatologists is limited. (James et al., 2007). 
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